Kerastem Technologies announce that the Company has received notice of conditional approval from the U.S. FDA Center For Biologics Evaluation and Research (CBER) Office of Cellular, Tissue and Gene Therapies

This content is restricted to site members. If you are an existing user, please log in. New users may register below.

Existing Users Log In